Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
nuv-422 save search
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
Published: 2022-08-01 (Crawled : 13:00) - biospace.com/
NUVB | $2.6 0.78% 0.0% 1.7M
|
|
| O: -0.72%
H: 2.55%
C: -9.12%
nuv-422 program
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
NUVB | $2.6 0.78% 0.0% 1.7M
|
|
| O: -1.31%
H: 0.12%
C: -11.97%
nuv-422 fda phase 1 clinical hold
Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme
Published: 2021-12-15 (Crawled : 13:00) - biospace.com/
NUVB | $2.6 0.78% 0.0% 1.7M
|
|
| O: -1.17%
H: 5.65%
C: 3.08%
nuv-422 fast track designation treatment fda fast track fda fast track designation glioblastoma
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
Published: 2021-12-13 (Crawled : 13:00) - biospace.com/
NUVB | $2.6 0.78% 0.0% 1.7M
|
|
| O: -0.11%
H: 0.0%
C: 0.0%
nuv-422 new drug treatment fda clearance prostate cancer application drug fda clearance cancer
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
Published: 2021-12-08 (Crawled : 13:00) - biospace.com/
NUVB | $2.6 0.78% 0.0% 1.7M
|
|
| O: -4.45%
H: 2.86%
C: 1.27%
new drug treatment fda clearance application drug fda clearance cancer breast cancer
Niu Technologies to Release Third Quarter 2021 Results on Nov 22, 2021
Published: 2021-11-01 (Crawled : 07:00) - globenewswire.com
NIU | $1.935 -4.68% -4.91% 290K
|
Consumer Durables
|
| O: 0.92%
H: 3.33%
C: 2.08%
results
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas
Published: 2021-03-11 (Crawled : 13:01) - biospace.com/
NUVB | $2.6 0.78% 0.0% 1.7M
|
|
| O: 1.86%
H: 7.83%
C: 5.32%
treatment drug granted grant designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.